Home/Filings/4/0001610717-24-000164
4//SEC Filing

Easom Eric 4

Accession 0001610717-24-000164

CIK 0001880438other

Filed

Mar 17, 8:00 PM ET

Accepted

Mar 18, 7:26 PM ET

Size

29.5 KB

Accession

0001610717-24-000164

Insider Transaction Report

Form 4
Period: 2024-03-15
Easom Eric
DirectorChief Executive Officer
Transactions
  • Award

    Common Stock

    2024-03-15+99,000101,130 total
  • Award

    Stock Option (right to buy)

    2024-03-15+198,000198,000 total
    Exercise: $3.00Exp: 2034-03-14Common Stock (198,000 underlying)
Holdings
  • Common Stock

    (indirect: See Footnote)
    97,058
  • Common Stock

    (indirect: See Footnote)
    97,058
  • Common Stock

    (indirect: See Footnote)
    1,015,766
Footnotes (5)
  • [F1]These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.
  • [F2]Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
  • [F3]Consists of shares of Common Stock held by the C Easom Irrevocable Trust dated October 8, 2021.
  • [F4]Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.
  • [F5]The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.

Issuer

AN2 Therapeutics, Inc.

CIK 0001880438

Entity typeother

Related Parties

1
  • filerCIK 0001914503

Filing Metadata

Form type
4
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 7:26 PM ET
Size
29.5 KB